Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
Tag facets appear after tag usage counts are rebuilt.
Rubrik reported FY2026 revenue of $1.3 billion, FY2026 operating cash flow of $282.9 million, a FY2026 net loss of $348.8 million and $380.2 million of cash. The thesis depends on subscription durability, data security demand, operating leverage, cash conversi
OpenQ2 Holdings reported FY2025 revenue of $794.8 million, Q1 2026 revenue of $216.5 million, FY2025 operating cash flow of $201.5 million and Q1 2026 net income of $26.6 million. The thesis depends on banking software demand, subscription durability, margin expan
OpenOkta reported FY2026 revenue of $2.9 billion, FY2026 operating income of $149 million and FY2026 operating cash flow of $884 million. The thesis depends on identity demand, retention, remaining performance obligations, margin discipline and security-platform c
OpenA Microsoft five-year double thesis focused on Azure AI demand, Copilot monetization, enterprise distribution, capital intensity, and regulatory risk.
OpenA Coverage Bootstrap Microsoft company evaluation covering Azure, Microsoft 365, Copilot, AI capex, enterprise distribution, security, gaming, regulation, and valuation setup.
OpenGitLab reported FY2026 revenue of $955.2 million, gross profit of $834.5 million, operating loss of $70.5 million and operating cash flow of $232.9 million. The setup depends on DevSecOps adoption, platform consolidation, gross-margin durability, operating dis
OpenA Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenA Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenAgenus has pushed BOT plus BAL into a global Phase 3 colorectal cancer trial and is generating early access revenue, but the current thesis is a race between regulatory progress and financing pressure: Q1 cash was $35.0M, operating cash flow was negative, the
OpenC3.ai ended FY2026 with preliminary revenue inside guidance and a large cash and investments balance, but the latest evidence is dominated by a sharp revenue reset, weak Q3 gross margin, negative free cash flow, a 26% workforce reduction and Thomas Siebel's re
OpenAI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future de
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenActivate Energy has no wells, no operating revenue, and no target yet. The source-backed story is a $230.6 million trust account, a December 2027 deal clock, oil-and-gas sponsor ambition, and a structure where Class A shares and warrants carry very different r
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.